doi: 10.1093/her/cym052, 119 PykeC.HellerR
Common side effects of both drugs include nausea, vomiting, diarrhea, abdominal pain, and constipation, with specific precautions against using either medication for patients with a history (or family history) of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
As such, its important to find quality sources of protein and amino acids
Its about the kind of healthcare system were buildingone where long-term metabolic risk is managed through lifelong pharmacology
Nevertheless, clinicians should continue following established precautions and reviewing patient history before initiating therapy
The FDA recently announced that the national shortage of semaglutide and tirzepatide is over and has notified compounding pharmacies that they must stop manufacturing these medications by May 2025